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“When swimming with sharks, don’t bleed when bitten” 
― Peter Aspelin  
 
 
  
ABSTRACT 
Background:  With increasingly ageing populations comes an increased prevalence of 
cognitive impairment and dementia. The pathophysiology behind dementia is still unknown, 
and there is no cure. Microscopic bleeds in the brain parenchyma, so called cerebral 
microbleeds, are common in ageing populations, as well as in dementia and stroke, and are 
primarily a marker of small vessel disease. Due to their high prevalence in memory clinic 
populations, microbleeds have been hypothesized to be of importance in the cognitive 
impairment disease process.  
Purpose: To cross-sectionally study the detection and clinical implications of cerebral 
microbleeds in cognitive impairment. 
Study I showed that microbleeds are common in cognitive impairment (22% prevalence), 
and especially in vascular dementia (59% prevalence). Microbleeds are associated with 
hypertension, male gender, high age, and increase with increasing risk factors. Topography of 
microbleeds is predominantly lobar and occipital in Alzheimer disease. The microbleed 
topography varies depending on underlying diagnosis and risk factors.  
Study II showed that susceptibility weighted imaging increases the prevalence and number 
of microbleeds detected on 3.0T magnetic resonance imaging. Inter-rater agreement of 
microbleeds is excellent on T2* and susceptibility weighted imaging, across raters of 
different experience. Only minor differences in clinical associations were noted across 
different sequences.  
Study III showed that amyloid β42 levels were lower in the cerebrospinal fluid with a high 
number of microbleeds. This was true in the whole cohort (n=1039), Alzheimer disease and 
mild cognitive impairment. In the whole cohort cerebrospinal fluid/serum albumin ratios 
were higher with increasing number of microbleeds. In multivariate regression analysis low 
amyloid levels in the cerebrospinal fluid with increasing number of microbleeds held true. 
White matter hyperintensities were likewise associated with low amyloid β42 levels, whereas 
lacunes were associated with higher amyloid levels in the cerebrospinal fluid. 
Study IV showed that lobar microbleeds are associated with lower amyloid β42 levels in the 
cerebrospinal fluid, in the whole cohort and Alzheimer disease. Deep and infratentorial 
microbleeds showed tendencies to be associated with higher amyloid and lower tau levels in 
the cerebrospinal fluid. Multivariable logistic regression analysis showed that white matter 
hyperintensities and lacunes were associated with lobar and deep microbleeds.  
Conclusions: Cerebral microbleeds are best detected with susceptibility weighted MRI and 
are common in a memory clinic. Microbleeds show varying associations based on 
topography. Especially lobar microbleeds are associated with low cerebrospinal fluid 
amyloid, and specifically in Alzheimer disease, suggesting that primarily lobar microbleeds 
may be of importance in cognitive impairment.  
SAMMANFATTNING 
Bakgrund: Kognitiv svikt samt demens ökar i takt med att befolkningsåldern globalt ökar. 
Patofysiologin bakom demens är fortfarande okänd och det finns inget bot. Mikroskopiska 
blödningar i hjärnan, så kallade cerebrala mikroblödningar, är en markör för småkärlssjuka, 
och är vanliga i åldrande populationer, samt hos patienter med demens och stroke. Till följd 
av deras höga prevalens i grupper med stroke samt demens har mikroblödningar ansetts vara 
av vikt i sjukdomsprocessen hos patienter med kognitiv svikt. 
Syfte: Att i tvärsnittsstudier utforska cerebrala mikroblödningar inom kognitiv svikt, deras 
implikationer, associationer och detektionsmetoder. 
Studie I visar att mikroblödningar är vanligt förekommande inom kognitiv svikt (22% 
prevalens), och är som mest vanligt inom vaskulär demens (59% prevalens). 
Mikroblödningar är associerade med hypertension, manligt kön och hög ålder, och ökar med 
ökande antal riskfaktorer. Mikroblödningar är främst lokaliserade i hjärnloberna, och främst 
occipitalt inom Alzheimers sjukdom. Mikroblödningslokalisation varierar beroende på 
underliggande orsak och association med riskfaktorer.  
Studie II visar att susceptibilitets-viktade sekvenser leder till ökad prevalens och ökat antal 
detekterade mikroblödningar på 3.0T magnetresonanstomografi. Överensstämmelse mellan 
raters av mikroblödningar är utmärkt på T2* samt susceptibilitets-viktade sekvenser, även 
hos raters med olika erfarenhet. Enbart små skillnader i kliniska associationer till 
mikroblödningar noterades för de olika magnetkamera-sekvenserna.  
Studie III visar att amyloid β42-nivåer minskar i cerebrospinalvätska med ökat antal 
mikroblödningar, för hela kohorten, Alzheimers sjukdom och lindrig kognitiv svikt. Ration 
för albumin i cerebrospinalvätska/serum var högre med ökande antal mikroblödningar. Låga 
amyloid β42-nivåer i cerebrospinalvätska var associerade med ökande antal mikroblödningar 
samt vitsubstansförändringar. Lakuner var associerade med höga amyloid β42-nivåer i 
cerebrospinalvätska.  
Study IV visar att mikroblödningar i hjärnloberna är associerade med lägre amyloid β42-
nivåer i cerebrospinalvätska, i hela kohorten samt Alzheimers sjukdom. Djupa och 
infratentoriella mikroblödningar visar tendenser till att vara associerade med högre amyloid 
β42- och lägre tau-nivåer i cerebrospinalvätska. Multivariabla logistiska regressionsanalyser 
visar att vitsubstansförändringar och lakuner är associerade med mikroblödningar i hjärnlober 
samt djupa områden i hjärnan. 
Slutsats: Cerebrala mikroblödningar är bäst detekterade med susceptibilitets-viktade 
sekvenser och är vanliga inom en minnesklinik. Mikroblödningar och olika associationer 
varierar beroende på blödningens lokalisation. Särskilt mikroblödningar i hjärnloberna visar 
associationer till låga värden av amyloid i cerebrospinalvätska, och specifikt inom 
Alzheimers sjukdom. Sannolikt är primärt mikroblödningar i hjärnloberna av vikt hos 
patienter med kognitiv svikt. 
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1 INTRODUCTION  
1.1 COGNITIVE IMPAIRMENT 
Cognitive impairment is a loss in cognitive function, whether subjective or objectively 
observed. Dementia, prestages of dementia and subjective cognitive impairment (SCI) may 
all be termed cognitive impairment. With increased ageing of populations, the prevalence of 
cognitive impairment, and especially Alzheimer disease (AD), is expected to rise1,2. In 2010 
35.6 million people lived with dementia worldwide; this number is expected to approximately 
double every 20 years3. The total estimated worldwide cost of dementia is US$ 818 billion4. 
However, disease pathology still remains elusive, and there is currently no treatment.  Figure 
1 shows the global impact of dementia.  
 
Figure 1. The global impact of dementia. Reprinted by permission from Alzheimer’s disease 
international, World Alzheimer Report 2015.  
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1.1.1 Diagnoses in a memory clinic 
AD is the most common form of dementia and accounts for 60-80% of dementias5,6. The 
hallmarks of AD are amyloid plaques, consisting of a core of amyloid β (Aβ) 42, and 
neurofibrillary tangles (NFT) composed of paired helical filaments and hyperphosphorylated 
tau5. The pathophysiology of AD remains elusive. Despite several hypotheses proposed, such 
as the amyloid cascade hypothesis, cholinergic hypothesis, inflammatory hypothesis, and the 
vascular hypothesis, no hypothesis has exhaustively and rationally been able to delineate AD 
pathophysiology7–10. Diagnosis of AD is based on the clinical presentation of dementia and 
cognitive decline with emphasis on amnesia11. Increased certainty may be added through the 
use of cerebrospinal fluid (CSF) analysis of biomarkers Aβ 42, total tau (T-tau) and 
phosphorylated tau (P-tau)12 as well as imaging. Recently, the research based AD criteria 
were revised to increase simplicity and availability of diagnosis, as well as incorporating 
biomarkers such as neuropsychological testing and imaging to improve diagnostic certainty13. 
Figure 2 shows positron emission tomography (PET) amyloid imaging with the Pittsburgh 
compound B (PiB) and fludeoxyglucose (FDG)14, which may aid diagnosis of AD, similar to 
CSF biomarkers. Treatment to date consists of acetylcholinesterase inhibitors and N-Methyl-
D-aspartate (NMDA) receptor antagonists10. Novel anti-amyloid, as well as anti-tau 
therapeutics are now under trial, and may prove to be important assets in the treatment of 
AD5,15. 
 
Figure 2. Amyloid deposition as seen by PiB and glucose uptake, as represented by FDG in 
Alzheimer disease and healthy controls. Reprinted by permission from John Wiley and Sons: 
Annals of Neurology14, copyright 2004. 
Mild cognitive impairment (MCI) includes the symptomatic prestage of AD. AD pathology is 
thought to begin years, and possibly decades, before the presentation of clinical 
symptoms16,17. Diagnostic criteria of MCI include cognitive deterioration but without 
significant impairment limiting life16,18. Far from all patients with MCI convert to AD, and it 
is still unclear what causes progression to dementia. Subjective cognitive impairment is as the 
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name suggests a cognitive impairment that cannot 
be objectively verified, but is solely subjective19. 
Subjective cognitive impairment (SCI) has been 
suggested to be the very preclinical stage of AD, 
although the group is undeniably diverse, and not 
everyone progresses to AD16,19. Figure 3 and 4 
show the hypothesized progression from the 
preclinical stage to dementia. 
 
Lewy body dementia (LBD) is thought to be the second 
most common dementia, constituting around 10-15% of 
all dementias20, although it is debatable whether the second position is shared with vascular 
dementia or not21. The hallmarks of LBD consist of α-synuclein Lewy bodies, and clinical 
features include visual hallucinations and parkinsonism20,22. Parkinson disease dementia 
(PDD) is distinguished from LBD by the onset of dementia; if dementia presents within 12 
months of parkinsonism the diagnosis is considered to be LBD, whereas more than 12 
months of parkinsonism before dementia qualifies as PDD20,22.  
 
Figure 4. Biomarkers in time during the progression to dementia. Reprinted by permission 
from Elsevier: Alzheimer’s & Dementia16, copyright 2004. 
Vascular dementia (VaD) is in turn also considered to be one of the most common dementias 
second to AD23. It defines all dementias resulting from a vascular pathology23. However, 
depending on the definition, it may be argued that the term vascular dementia has, with the 
dawn of increased small vessel disease (SVD) research, become obsolete. There is a 
considerable overlap between VaD and AD,24 and most, if not all dementias can be argued to 
Figure 3. The progression to dementia. 
Reprinted by permission from Elsevier: 
Alzheimer’s & Dementia16, copyright 2004. 
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have a vascular component. Cerebral amyloid angiopathy (CAA), amyloid deposition in the 
media and intima of small vessel walls is thought to be present in healthy ageing and almost 
all patients with AD25–27. Cognitive decline due to CAA has been seen26,28–30. The 
classification of VaD includes: strategic-infarct dementia, cortical vascular dementia, 
subcortical ischemic dementia, hypoperfusion dementia, hemorrhagic dementia and 
dementias resulting from arteriopathies23. Primary prevention, by early on attacking 
cardiovascular as well as cerebrovascular risk factors, is what is practiced and thought to 
reduce the incidence of VaD23,31.  
Frontotemporal lobe dementia (FTD) is characterized by selective degeneration and atrophy 
of the frontal and temporal lobes32. Prevalence is considered less than the above-mentioned 
dementias; studies have shown a prevalence range of 4-15/100 000 in populations younger 
than 65 years32,33. Disease presentation often occurs in the third to ninth decade of life, 
although around the sixth decade is more common32. Three clinical variants of FTD have 
been described, behavioral variant FTD, semantic dementia, and progressive nonfluent 
aphasia33.  
Alcohol related dementia (ARD) and Wernicke-Korsakoff syndrome are both a result of 
excessive alcohol consumption. ARD is still debated as whether the effects are due to ethanol 
toxicity in itself or the related lack of nutrition, vitamin deficiencies (e.g. thiamine), the life 
style with increased risk of head trauma, and the higher number of vascular risk factors34. 
Thiamine deficiency is the cause of Wernicke encephalopathy, characterized by the classical 
triad ophthalmoplegia, ataxia and dementia34. Korsakoff syndrome, caused by thiamine 
deficiency, in turn denotes an acute onset of cognitive decline, and often occurs together with 
Wernicke encephalopathy, hence the name Wernicke-Korsakoff syndrome34. Treatment 
includes cutting down on, or giving up, alcohol, as well as high doses of thiamine34. 
Other diseases, and secondary causes of cognitive impairment also exist in a memory clinic. 
Creutzfeldt-Jakob disease, and cognitive impairment associated with other disease panoramas 
such as multiple sclerosis, aids and amyotrophic lateral sclerosis, may also surface in a 
memory clinic. Secondary causes of cognitive impairment include, amongst others, subdural 
hematoma and slow growing tumors. Clinical dementia with an unknown cause is termed 
unspecified dementia.  
1.1.2 Cerebrospinal fluid measurements 
CSF analysis, and thus a lumbar puncture, is done routinely in memory clinic investigations 
in Sweden. It yields important differential diagnostic data in the reasoning of diagnosis. Since 
the CSF is in constant direct contact with the brain it also reflects the biochemical state of the 
brain12. Biomarkers usually analyzed include Aβ 42, T-tau, P-tau and CSF/serum albumin 
ratios. A low Aβ 42 level in the CSF is thought to reflect increased amyloid deposition in the 
brain, and is what is expected in AD35,36. High T-tau and P-tau levels are commonly seen in 
AD, although unspecific, they reflect neurodegeneration and NFTs respectively35. CSF/serum 
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albumin ratios reflect the integrity of the blood brain barrier (BBB), increases in the ratio 
reflecting increased permeability37.  
1.1.3 Neuropsychological testing 
Neuropsychological testing is routinely done in memory clinic investigations. Episodic 
memory deficits are usually the first line of cognitive impairment in AD11. Semantic memory 
impairment, as well as concentration and visuospatial difficulties may also occur in AD11. 
The mini mental state examination (MMSE) is an easy and efficient screening tool for 
cognitive impairment. Due to the ease in which it can be clinically used it is one of the most 
common tests of cognitive screening, and the maximum score is 3038. MMSE tests language, 
memory, attention and figure copying amongst others38,39. 
1.1.4 Imaging 
Imaging has gained importance in the diagnostic reasoning, and is increasingly a cornerstone 
in memory clinic investigation. Computed tomography (CT) of the brain is quick and 
efficient, and still probably the most used modality as part of memory clinic investigations 
worldwide. Magnetic resonance imaging (MRI) shows a great level of detail, and is 
increasingly replacing CT as an examination. MRI is ideal for maximal differential diagnostic 
reasoning, and makes imaging of SVD markers possible. 
With imaging it is of importance to first rule out secondary causes of dementia such as an 
expansive mass or hydrocephalus. In detailed assessment of cognitive impairment, atrophy 
may be evaluated with the use of different rating scales40. Rating scales for both CT and MRI 
include the global cortical atrophy scale,41 the Koedam scale assessing for parietal atrophy, 
the medial temporal atrophy scale, and the Fazekas42 or the age related white matter changes 
scale43. PET imaging is of use in the differential diagnostic reasoning, and FDG PET is the 
most commonly used tracer. Additional assessment can be done on MRI, where markers of 
SVD such as cerebral microbleeds (CMBs), lacunes, enlarged perivascular spaces, cortical 
superficial siderosis and white matter hyperintensities (in a higher level of detail)30, may be 
analyzed. Figure 5 depicts the distribution of CAA and related SVD markers. 
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Figure 5. CAA related markers in the brain. Reprinted by permission from Oxford University 
Press: Brain44, copyright 2011, and Dr Andreas Charidimou. 
1.2 CEREBRAL MICROBLEEDS 
1.2.1 Etiology 
Microscopic bleeds in the brain parenchyma, CMBs, 
most frequently arise from SVD. SVD is the disease of 
microscopic vessels in the brain30. The two most 
common etiologies of SVD are: 1. CAA, which is 
amyloid deposition in the media and intima of vessel 
walls, leading to vessel fragility, disruption of the vessel 
walls, possible microaneurysms, blood extravasation 
and sometimes also luminal occlusion30. Figure 6 
shows a histopathological image of CAA. 2. 
Hypertensive arteriopathy is hypertensive related 
damage, primarily affecting the deep perforating 
vessels30,45. Pathophysiology includes 
arteriolosclerosis, fibrohyaline deposits narrowing the 
lumen, thickening of the vessel wall, atherosclerosis and microaneursyms, amongst 
others30,45. CAA and hypertensive arteriopathy are thought to have different locations, with 
CAA mainly affecting the brain lobes and hypertensive arteriopathy the deep regions of the 
brain30,45. Figure 7 depicts the pathophysiology of CAA. Since SVD affects small vessels in 
the brain, which cannot be imaged per se, imaging markers of SVD are used as signatures of 
the disease30, seen in Figure 8. CMBs are one imaging marker of SVD. Their topography 
follows that of SVD, with lobar CMBs representing CAA, and deep CMBs, hypertensive 
arteriopathy.  
1.2.2 Detection 
CMBs can only be detected in vivo by MRI, and are usually only seen with hemosiderin 
sensitive sequences such as the T2* and susceptibility weighted imaging (SWI) sequence29,45. 
Since CMBs are supraparamagnetic, they introduce inhomogeneities in the magnetic field, 
causing rapid decay of the MRI signal, termed the susceptibility effect29,46. This leads to 
CMBs having a hypointense appearance on MRI29. MRI parameters affect the detection of 
CMBs; for instance an increased time to echo (TE) leads to increased time for dephasing and 
an enlarged susceptibility effect, i.e. appearance of CMBs29,47. Other ways of increasing 
CMB detection include the use of SWI, higher field strength and thinner slice thickness29,48–
50.  The microbleed anatomical rating scale (MARS) is a standardized rating scale for 
CMBs51. Mimics for CMBs, that are detailed in the MARS, and need to be avoided in CMB 
rating include calcifications, cross-sectioned vessels, partial volume artifacts and cavernomas, 
amongst others29,51. Histopathological studies have shown a good correspondence between 
CMBs on MRI and histopathology52.  
Figure 6. Cerebral amyloid angiopathy seen 
in vessels stained with congo red. Reprinted 
by permission from John Wiley and Sons: 
Neuropathology and applied neurobiology45, 
copyright 2012. 
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Figure 7. The pathophysiology and markers of CAA. Reprinted by permission from Oxford 
University Press: Brain44, copyright 2011. 
 
1.2.3 Implications 
CMBs have been detected since the 1990s, with the use of hemosiderin sensitive 
sequences29,53,54. Initially hemosiderin sequences were only included for research purposes, 
and it took time before the sequences were incorporated in clinical MRI protocols. At the 
radiology department at the Karolinska university hospital it was first in and around 2006 that 
hemosiderin sensitive sequences were introduced in routine MRI protocols. It was quickly 
noted that especially two populations had CMBs more frequently than others: patients with 
cognitive impairment and stroke. At that time CMBs were still a dilemma, and their clinical 
implications remained unknown. The worldwide increased detection, especially in these two 
populations, prompted a surge of research on the topic, such as this PhD thesis.  
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The higher frequency of CMBs in memory clinic populations, around 18-32%55–59,  when 
compared to healthy ageing populations, with a prevalence usually in the range of 6-11%60–62, 
suggests an involvement of CMBs in cognitive impairment63. CMBs were hypothesized to 
bridge the vascular theory in AD and the amyloid hypothesis63. The hypothesis is that 
abnormal amyloid precursor protein cleavage may lead to abnormal accumulation of Aβ in 
vessel walls and thus vessel fragility; at the same time atherosclerosis/arteriolosclerosis 
would contribute to decreased vessel wall integrity. Both these processes would eventually 
lead to CMBs. The blood extravasation and vessel wall fragility would open up for influx of 
plasma components, that would trigger neurodegeneration, and eventually AD63. Further 
hypotheses suggest that amyloid plaques stem from the vasculature and align with CMBs64,65.  
Figure 8. MRI markers of SVD, which are in order: a) Cerebral microbleeds b) Cortical 
superficial siderosis c) Enlarged perivascular spaces. d) White matter hyperintensities. e) 
Lacune. f) Cortical microinfarct. 
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2 AIMS OF THIS THESIS 
With increased detection of CMBs, due to incorporation of hemosiderin sensitive MRI 
sequences in routine clinical protocols, questions were raised. The clinical implications of 
CMBs were unknown, and the fact that they were more frequent in memory clinic 
populations raised hypotheses that they may interact with the neurodegenerative process in 
cognitive impairment. The purpose of this thesis was to investigate CMBs in a memory clinic 
population, its prevalence, detection method, implications and associations. 
The specific objectives of each study were:  
Study I To study the prevalence, topography and associations as well as clinical 
implications of CMBs in a memory clinic.  
 
Study II To determine which MRI sequence should be used in the rating of CMBs, if 
the SWI and T2* are comparable with regards to inter-rater agreement and 
clinical associations with CMBs, across sequencs. 
 
Study III To determine how CSF biomarkers (Aβ 42, T-tau, P-tau and CSF/serum 
albumin ratios) are associated with CMBs, and to see if: 1. Associations 
between biomarkers and CMBs increase in the continuum of cognitive 
impairment from SCI to AD. 2. Biomarkers reach pathological levels with 
increased numbers of CMBs. 3. The joint presence of amyloid pathology and 
hypertensive arteriopathy would pronounce the relation with CSF 
biomarkers. 
 
Study IV To study: 1. The association between CSF biomarkers and CMB topography. 
2. The prediction by other MRI markers of SVD and CSF biomarkers, in the 
likelihood of having lobar versus deep/infratentorial CMBs. 
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3 MATERIALS AND METHODS  
3.1 ETHICAL CONSIDERATIONS  
For all studies: Informed consent was obtained from each patient, according to the declaration 
of Helsinki. Ethical approval was obtained from the regional ethical board, Stockholm, 
Sweden (registration numbers: 2012/2038-32, 2013/363-32). 
3.2 PATIENTS 
This thesis is the first thesis in the cross-sectional Karolinska Imaging Dementia Study 
(KIDS). The KIDS aims to investigate SVD and other imaging markers in a memory clinic 
population. Inclusion criteria for the cohort used in Studies I, III and IV were patients 
undergoing memory clinic investigation with an accompanying MRI scan, and an MRI 
protocol including hemosiderin sensitive sequences (SWI/ T2*). Exclusion criteria were 
insufficient scan quality or prior history of brain trauma. A total cohort of 1504 patients were 
enrolled, encompassing 10 diagnostic groups. In study III and IV inclusion criteria was 
restricted to the above, and additionally CSF biomarker analysis leading to a cohort of 1039 
patients. In study II, the inclusion criteria were restricted to patients with both the SWI and 
T2* on 3.0T MRI imaging, yielding a cohort of 246 patients. Diagnoses were set according to 
the ICD-1066 in multidisciplinary rounds, with consideration of all data, such as imaging, lab 
tests, neuropsychological testing, and a routine clinical work up. All diagnoses and the ICD-
codes associated are seen below in Table 1. All patients’ clinical notes were analyzed and 
data extracted. For instance, to classify as hypertensive the patient either had to have the 
diagnosis in their medical record, or the appropriate medication.  
Table 1. Diagnoses and accompanying ICD-codes 
Diagnosis (n=1504) ICD-codes 
Subjective Cognitive Impairment 
(n=385) 
Z03.2A, Z03.3 and R41.8A 
Alcohol Related Dementia (n=20) F10.6, F10.7a 
Alzheimer’s Disease (n=423) F00.0 (early onset, n=176), F00.1 (late onset, n=146), F00.2 
(atypical disease with vascular components, n=96), F00.9 
(unspecified Alzheimer’s disease, n=5) 
Asymptomatic Hereditary Dementia 
(n=45) 
Z31.5 
Frontotemporal Lobe Dementia (n=30) F0.70, F02.0 
Mild Cognitive Impairment (n=418) F06.7 
Parkinson’s Dementia (n=21) F02.3, G31.8a 
Unspecified Dementia (n=55) F03.9 
Vascular Dementia (n=54) F01.1, F01.2, F01.3, F01.9 and CADASIL (4 patients) based on 
I63.8 
Other Disorders (n=53) Depression, hallucination, delirium, other reactions to severe stress, 
psychosis, bipolar disease, amnesia, systemic lupus erythematosus 
encephalopathy, dysphasia, degenerative diseases in the basal 
ganglia, hydrocephalus, narcolepsia, Creutzfeldt Jacob disease, 
supratentorial epidermoid tumour, cerebral infarctions, anemia, 
hereditary ataxia, multiple system degeneration and progressive 
supranuclear palsy. 
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3.3 MAGNETIC RESONANCE IMAGING  
All patients had their MRI done at the radiology department at the Karolinska university 
hospital, Stockholm, Sweden. Patients were scanned in three different scanners (Siemens 
Medical Systems, Erlangen, Germany) noted in Table 2. All patients had a T1, T2, FLAIR, 
diffusion weighted sequences as well as the SWI and/or T2* sequences. 
Table 2. MRI parameters for the T2*/SWI. 
 
 
 
 
 
 
 
3.4 RADIOLOGICAL ASSESSMENT 
All images were assessed for CMBs, WMH and lacunes according to standardized 
criteria51,67. CMBs were assessed according to the MARS51 as rounded hypointensities in the 
brain parenchyma on axial SWI/T2* sequences. Care was taken to avoid rating mimics such 
as calcifications, cross-sectioned vessels, partial volume artifacts and cavernomas. For 
instance hypointensities in the globus pallidus were not rated and were regarded as 
physiological iron deposition/calcifications. Further, if a DVA was seen, a potential 
microbleed in the vicinity was not rated as it could represent a small cavernoma. WMH were 
rated on axial fluid attenuated inversion recovery (FLAIR) sequences, and defined as 0 = 
none or single punctate, 1 = multiple punctate, 2 = early confluent, 3 = large confluent, 
according to the Fazekas scale42. Lacunes were defined as 3-15mm in size, with CSF signal 
on T2, FLAIR and T1.  
In study I, images were analyzed by Sara Shams, a trained rater and at that time an MD/PhD 
student, for CMBs. All images were analyzed in a blinded manner without knowledge of 
patient data; additionally intra-rater agreement was performed. Inter-rater agreement was 
done blinded by Juha Martola, a neuroradiology attending, on 100 randomly selected patients 
in the cohort. 
In study II, three raters were chosen, Sara Shams, by then an MD/PhD student, Juha Martola 
and Lena Cavallin, both attending neuroradiologists. All raters did a blinded, randomized and 
independent analysis of CMBs according to the MARS on a T2*, SWI and a reformatted 
thick slice SWI. For all raters, first CMBs on the T2* were rated, three days later CMBs on 
the SWI were rated and six months later on the tSWI. Images were randomized between each 
Siemens Magnetom  Symphony Avanto Trio 
Field strength (T)  1.5 1.5 3.0 
T2* Time to echo 25 26 20 
 Time to repeat 792 800 620 
 Flip angle 20° 20° 20° 
 Slice thickness 5.0 5.0 4.0 
SWI Time to echo - 40 20 
 Time to repeat - 49 28 
 Flip angle - 15° 15° 
 Slice thickness - 4.0 1.6 
Patients (n) - 453 681 370 
  13 
rating, and ratings were done in a blinded manner and continuously over a single day. 
Additionally WMH analysis was performed according to the Fazekas scale, as defined 
above42. 
In study III and IV, Sara Shams and Juha Martola jointly (i.e. by consensus) analyzed all 
images for CMBs, lacunes and WMH.  
3.5 CEREBROSPINAL FLUID ANALYSIS 
Lumbar puncture was done as part of the memory clinic investigation. CSF was collected in 
10 ml polypropylene tubes, and centrifuged within 2 h, at 1900g for 10 min, and then frozen 
until analysis. Biomarkers measured were Aβ 42 (Innotest b-amyloid (1–42)), T-tau 
(Innotest hTau-Ag) and P-tau (Innotest Phospho-tau (181 P) (Innogenetics, Ghent, 
Belgium), all measured with sandwich type enzyme-linked immunosorbent assay. Blood 
samples were collected at the same time as lumbar puncture for analysis of the CSF/serum 
albumin ratio. All analyses were done at the department of clinical chemistry, Karolinska 
university hospital, Stockholm, Sweden. The team involved in the analyses was unaware of 
the diagnoses and study hypotheses. 
3.6 STATISTICAL ANALYSIS  
General: Descriptive variables are presented as means (±SD) for parametric variables and 
median and interquartile range (IQR) for nonparametric data. P<0.05 was set as the threshold 
of statistical significance. SPSS 22.0 was used for statistical analysis.  
Study I: Chi-squares and Fisher’s exact test were used in the assessment of categorical data. 
Mann-Whitney U and the Kruskall-Wallis tests were used for continuous nonparametric data. 
Logistic regression analysis was used with CMBs dichotomized into present/absent as a 
dependent variable and diagnosis, with SCI as a reference, as an independent variable. The 
prior model was adjusted for hypertension, hyperlipidemia, diabetes, sex, age, MRI field 
strength (1.5/3.0T) and CMB sequence (SWI/T2*). Another logistic regression model was 
created to assess the impact of risk factors on CMBs. CMBs (present/absent) were used as a 
dependent variable, with the number of risk factors used as an independent variable. A third 
negative binomial regression model was constructed, and CMBs numbers/ numbers in 
different topographies were used as a dependent variable and risk factors as independent 
variables. The both two latter models were adjusted for MRI field strength (1.5/3.0T) and 
CMB sequence (SWI/T2*). Bonferroni correction was applied for each P-value. 
Study II: McNemar and Wilcoxon signed rank tests were used to determine the differences 
between prevalence and number of CMBs, between sequences. Intra class correlation 
coefficient analysis was made for inter-rater agreement. Chi-squares were used for 
categorical data and Mann-Whitney U tests for continuous data. Negative binomial regression 
models were constructed with numbers of CMBs, for the different sequences, as dependent 
variables, and clinical parameters as independent variables. The models were subsequently 
corrected for age and sex. Bonferroni correction was applied for each P-value. 
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Study III: CSF-biomarkers were log-transformed to reach normal distribution. Analysis of 
variance (ANOVA) with post-hoc Bonferroni correction was used for comparison of CSF 
biomarkers in patients with zero, one and multiple (arbitrarily defined as six or more) CMBs. 
Multivariate linear regression analysis was used to determine associations between CSF 
biomarkers (dependent variable) and CMBs, WMH and lacunes as independent variables; the 
model was adjusted for MRI field strength (1.5/3.0T), CMB sequences (SWI/T2*), age and 
sex.  
Study IV: CSF-biomarkers were similarly log-transformed to reach normal distribution. 
Multivariate linear regression models with CSF biomarkers as dependent variables and 
CMBs, dichotomized into present/absent for different topographies, as independent variables. 
Multivariable logistic regression models with CMBs in different locations (deep/lobar) and 
probable CAA-related/unrelated were used as dependent variables and WMH, lacunes, CSF 
Aβ 42, T-tau, P-tau were used as independent variables. The model was adjusted for age, 
hypertension, diagnosis, MRI field strength (1.5/3.0T) and CMB sequence (SWI/T2*). 
Bonferroni correction was applied for each P-value. 
4 RESULTS  
4.1 STUDY I  
Prevalence: CMBs had a 22% prevalence (332/1504) in our memory clinic cohort. They 
were most common in patients with VaD, 59%, followed by 40% in ARD, 33% in 
unspecified dementia, 28% in AD, 24% in Pakinson’s dementia, 21% in MCI, 19% in other 
disorders, 17% in FTD, 13% in asymptomatic hereditary dementia and 11% in SCI. The 
prevalence and number (P<0.001) as well as presence of multiple CMBs (P=0.03) varied 
significantly between the different diagnoses. The odds of having CMBs in the different 
diagnostic groups are seen in Table 3. 
Topography: The most common location for CMBs in the whole cohort was lobar (84%), 
followed by infratentorial (30%), and deep (27%). In the separate diagnoses only AD had 
CMBs more significantly in the brain lobes (P=0.01), with the occipital lobe being the most 
common location in detailed analysis (P=0.007). 
Clinical associations: CMBs were significantly more frequent in male patients (P<0.001), 
patients with high age (P<0.001), and hypertension (P<0.001). MMSE scores were lower in 
patients with CMBs than without (P=0.02). In the separate diagnostic groups CMB 
prevalence was higher with hypertension in SCI (P=0.02), hyperlipidemia in MCI (P=0.03), 
male sex in AD, MCI and VaD (P<0.05), and high age in AD and MCI (P<0.05). In binomial 
negative regression analysis, with number of CMBs as a dependent variable, it was seen that 
male sex (in whole cohort, AD, MCI, VaD), high age (in whole cohort, AD, MCI) and 
hypertension (in whole cohort, SCI) were associated with increased numbers of CMBs 
(P<0.05). Hyperlipidemia (in whole cohort, MCI, VaD) and diabetes (in all large groups) 
were associated with a lower number of CMBs (P<0.001). Varying topography of CMBs was 
associated with different risk factors: hypertension was associated with high number of 
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CMBs in both lobar (in whole cohort, SCI) and deep/infratentorial locations (in whole cohort, 
AD, MCI) (P<0.05). Hyperlipidemia was associated with lower number of CMBs in 
deep/infratentorial locations in the whole cohort  (P<0.05). Low CMBs in both lobar and 
deep/infratentorial locations were associated with diabetes in MCI (P<0.05). Male sex was 
associated with high number of CMBs in lobar (AD) and deep/infratentorial regions in the 
whole cohort, and MCI, and with deep/infratentorial only in VaD (P<0.05). 
Infratentorial/deep and lobar (whole cohort and MCI; only lobar: AD) CMBs were associated 
with high age (P<0.05).  
Table 3. Odds ratios for CMBs in the different diagnoses. 
Adjustment is made for hypertension, hyperlipidemia, diabetes, sex, age, MRI field strength and CMB 
sequence.aP<0.001, bP<0.01 
 
4.2 STUDY II  
Prevalence/number of CMBs across sequences: On T2* the prevalence was 17% (43/246), 
on SWI 21% (51/246) and 20% (50/246) on thick slice SWI. The difference in prevalence 
and number of CMBs was significant when comparing SWI and T2* (P<0.05), and for 
number of CMBs between thick slice SWI and T2*. There was no significant difference 
between conventional thin slice SWI and thick slice SWI. Results were correspondingly 
similar in the different diagnoses. 
Inter-rater agreement: Inter-rater agreement across three raters with varying experience 
was excellent across sequences. Reasons for disagreement that were identified were CMBs 
close to vessels, lack of attention by the rater, multiple, pale and small CMBs.  
Clinical relevance: In univariate analysis of patients with and without CMBs an association 
was seen between patients with CMBs and high age (P=0.01) and high WMH score 
(P=0.006). The controlled negative binomial regression analyses showed an association 
between increased number of CMBs and AD, MCI, other dementias, age, male sex, current 
alcohol drinking, heredity for dementia, and increased WMH burden for all sequences 
Diagnosis OR for CMBs 
(95%CI) 
Adjusted OR for 
CMBs (95%CI) 
 
Subjective cognitive impairment (n=385) 
 
1.0 (Ref.) 1.0 (Ref.) 
Alcohol related dementia (n=20) 5.5 (2.1-14.2)a 4.0 (1.4-11.2)b 
Alzheimer’s disease (n=423) 3.2 (2.2-4.7)a 2.0 (1.2-3.1)b 
Asymptomatic hereditary dementia (n=45) 1.3 (0.5-3.2) 1.5 (0.5-4.1) 
Frontotemporal lobe dementia (n=30) 1.6 (0.6-4.5) 1.2 (0.4-3.4) 
Mild cognitive impairment (n=418) 2.2 (1.5-3.3)a 1.5 (0.9-2.3) 
Other disorders (n=53) 2.1 (0.9-4.4) 1.2 (0.5-2.8) 
Parkinson’s Dementia (n=21) 2.6 (0.9-7.4) 1.7 (0.5-5.7) 
Unspecified dementia (n=55) 3.1 (1.7-6.0)a 2.2 (1.0-4.4)a 
Vascular dementia (n=54) 10.9 (6.0-19.7)a 10.9 (6.0-19.7)a 
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(P<0.05). It was further seen that low number of CMBs was associated with anticoagulants, 
current smoking and hyperlipidemia. Only minor differences across sequences were noted.  
4.3 STUDY III  
CMBs and associations with CSF biomarkers: Patients with 0, 1 and ≥6 CMBs were 
compared. Aβ42 levels were significantly lower in patients with ≥6 CMBs when compared to 
patients with 1 or 0 CMBs (P<0.01). Aβ42 levels were significantly lower when comparing 
≥6 and 0 CMBs, in AD and MCI (P<0.05). In AD, as well as in AD and VaD with 
hypertension, T-tau and P-tau levels were lower in patients with ≥6 CMBs when compared to 
0 (P<0.05). CSF/serum albumin ratios were higher in patients with ≥6 CMBs when compared 
to 0 (P<0.001), in the whole cohort. 
Independent associations of CMBs with CSF biomarkers: In multivariate linear 
regression analysis with CMBs, WMH and lacunes in the same model, it was seen that CMBs 
were associated with low Aβ42 levels (P<0.01) in the whole cohort, AD and MCI. WMH 
were associated with low Aβ42 levels in the whole cohort and in AD (P<0.05). T-tau was 
high with increased WMH in the whole cohort and low in AD (P<0.05). CSF/serum albumin 
ratios were high with increased WMH. Aβ42 levels were high with lacunes in the whole 
cohort (P≤ 0.05).  
4.4 STUDY IV  
Topographies and associations with CSF biomarkers: Lobar CMBs were associated with 
low Aβ42 levels in the whole cohort, AD, MCI (P<0.05). P-tau showed a tendency to be 
lower with infratentorial CMBs in AD. No other associations were found. In more detailed 
brain topographies Aβ42 levels showed a tendency to be high with CMBs in the cerebellum 
in AD and the whole cohort (P<0.05, before Bonferroni correction). CMBs in the brainstem 
showed associations with low T-tau, P-tau, in the whole cohort and AD (P<0.05, before 
Bonferroni correction), and with high CSF/serum albumin ratio in MCI (P<0.05). Deep 
CMBs were associated with lower T-tau levels (P<0.05, before Bonferroni correction). 
Frontal CMBs were associated with low Aβ42 levels AD (P<0.001), and showed a tendency 
to be low in SCI (P<0.05, before Bonferroni correction). Temporal CMBs showed a tendency 
to be associated with low Aβ42 levels in the whole cohort and MCI (P<0.05, before 
Bonferroni correction). Occipital CMBs showed an association with low Aβ42 levels in the 
occipital lobe (P<0.01), AD and MCI (P<0.05, before Bonferroni correction), and higher 
CSF/serum albumin ratios in AD (P<0.05, before Bonferroni correction).  
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Prediction of CMBs through imaging and CSF biomarkers: Data is displayed in Table 4, 
below.  
Table 4. Prediction of different types of CMBs by CSF and imaging biomarkers  
(OR; 
95%CI; 
 p-value) 
Lobar CMBs Deep CMBs Probable CAA-
related CMBs  
(vs. no CMBs) 
Probable CAA 
unrelated CMBs 
(vs. no CMBs) 
WMH 1.68 (1.35-2.09); 
P<0.0001 
2.97 (2.08-4.25); 
P<0.0001 
1.86 (1.27-2.73); 
P=0.002 
1.78 (1.44-2.20); 
P<0.0001 
Lacunes 2.61 (1.69-4.04); 
P<0.0001 
1.93 (0.98-3.80); 
P=0.059 
4.11 (1.86-9.10); 
P<0.0001 
1.92 (1.22-3.04); 
P=0.005 
CSF Aβ42 0.11 (0.04-0.29); 
P<0.0001 
0.38 (0.07-2.14); 
P=0.274 
0.01 (0.00-0.03); 
P<0.0001 
0.51 (0.19-1.35); 
P=0.172 
CSF T-Tau 0.61 (0.23-163); 
P=0.325 
0.25 (0.05-1.23); 
P=0.089 
0.94 (0.11-8.36); 
P=0.959 
0.70 (0.26-1.89); 
P=0.484 
CSF P-tau 2.06 (0.61-6.91); 
P=0.244 
2.72 (0.39-19.05); 
P=0.311 
0.83 (0.06-11.08); 
P=0.888 
2.07 (0.60-7.12); 
P=0.247 
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5 DISCUSSION  
 
Study I: We show that CMBs are 
common in a memory clinic and that 
risk factor associations differ depending 
on diagnosis and topography. Our 
prevalence is in line with what other 
studies have shown15, as seen in Table 5.  
 
CMBs were most common in VaD in our 
cohort, which is rational, due to the 
amount of vascular risk factors in VaD. 
This was followed by a high prevalence 
of CMBs in ARD, which also makes 
sense, due to the alcohol related vascular 
risk factors such as diabetes, 
hypertension and hyperlipidemia. AD 
had a 28% prevalence, one of the highest 
in our cohort, which may be explained 
by the large amount of CAA in AD, 
almost all patients with AD thought to 
have CAA25,26.  
 
Lobar CMBs being most common in AD 
is also reasonable, due to the high 
amount of CAA in AD. Further, occipital 
CMBs being most common may be explained by the fact that CAA favors the brain lobes, 
and seems to have a predilection for the occipital lobe. Variance of risk factors with CMBs is 
further expected, due to the fact that deep and infratentorial CMBs are thought to represent 
hypertensive arteriopathy, and lobar CMBs CAA. Hypertension was however associated with 
both lobar and deep CMBs, which may suggest an overlap between CAA and hypertensive 
arteriopathy in our cohort. Male sex also showed an association with both infratentorial/deep 
and lobar CMBs, suggesting that CMBs, perhaps due to the increased vascular risk factors, 
are more common in male, as has been shown in another study83. 
 
General risk factor associations with CMB presence, independent of location, were 
hypertension, high age and male sex. MMSE was lower in patients with CMBs, in the whole 
cohort, in univariate analysis, most probably due to the high amount of CMBs in VaD and 
AD. CMBs and the possible impact on cognition is however not well investigated, and 
studies have shown varying results58,84–87. Increasing number of risk factors lead to higher OR 
for CMBs, showing that the risk of CMBs is at highest with accumulated risk factors.  
 
The limitations in our study include three different scanners and both T2* and SWI sequences 
used, although our regression models were corrected for these two variables. Advantages 
include a large cohort, representative of a typical memory clinic panorama, with thorough 
imaging analysis and memory clinic investigation.  
Study Prevalence, 
% (n) 
MRI Field 
Strength (T) 
Sequence 
68 33 (6) 3.0 T2* 
69 45 (66) 3.0 T2* 
70 26 (98) 3.0 T2* 
71 39 (26) 3.0 T2* 
72 12 (25) 3.0 T2* 
73 20 (32) 3.0 T2* 
74  33 (79) 3.0 SWI 
75  43 (17) 3.0 SWI 
76  48 (77) 3.0 SWI 
73 22 (35) 3.0 SWI 
77 28 (118) 3.0-1.5 SWI &T2* 
78 21 (117) 3.0–1.0 T2* 
79  20 (16) 1.5 T2* 
50 20 (10) 1.5 T2* 
55 32 (19) 1.5 T2* 
56 16 (8) 1.5 T2* 
57 18 (7) 1.5 T2* 
80 24 (132) 1.5 T2* 
81 18 (21) 1.5 T2* 
58 18 (23) 1.5 T2* 
82 33 (24) 1.5 T2* 
50 39 (19) 1.5 SWI 
Table 5. Prevalence of CMBs across different cohorts of 
cognitive impairment. 
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Study II: Our study shows that SWI increases the number and prevalence of detected CMBs. 
SWI is consequently, due to this fact, the recommended sequence to use in CMB detection. 
We note however that CMB detection is excellent across raters of different experience and 
sequences, and that clinical associations remain the same. Consequently, studies on CMBs 
are comparable with regard to clinical associations.  
 
Prior studies have shown favorable results promoting the SWI sequence48,50,88, although no 
difference has been noted in clinical associations between T2* and SWI50. Inter-rater 
agreement has been excellent throughout sequences in one study50, as well as better on 
SWI49. Prevalence and number of CMBs both increase with the use of SWI49,50. We, and 
Goos et al used a thicker reformatted SWI in order to differentiate the effect of the routinely 
thinner slice thickness in SWI vs. the intrinsic contrast enhancing properties of SWI. Thick 
SWI showed an increase in number and prevalence of CMBs detected, and the difference 
between thick and thin SWI was minor. Thin SWI, however, showed the highest increase in 
CMBs, which most certainly is due to the thinner slice thickness effect of SWI.  
 
Clinical associations were shown between CMBs and AD, MCI, and other dementias, which 
are all rational as seen in Study I. More surprisingly we saw the association of hyperlipidemia 
and lower number of CMBs, which is similar to that seen in Study I, this may represent a 
population well treated in terms of vascular risk factors, which in turn would explain the 
association with lower number of CMBs. Further surprising was the association between 
smoking and lower number of CMBs, similar to what has been shown prior50,89. 
Higher numbers of CMBs were associated with alcohol consumption, which is rational 
considering the high prevalence of CMBs in ARD.  
 
Strengths of our study include a large cohort, three raters with varying experience, and 
thorough rating methods with the standardized MARS. Phase or quantitative susceptibility 
maps may have further aided in the correct differentiation of CMBs and calcifications. 
 
Study III: We show that increased number of CMBs is associated with decreased levels of 
Aβ42, indicating increased amyloid deposition in the brain36. CSF/serum albumin ratios were 
increased with higher number of CMBs, most probably indicating a disrupted BBB. T-tau 
and P-tau were lower with higher number of CMBs, suggesting a lack of association between 
neurodegeneration and NFTs with CMBs.  
Prior studies have similarly shown an association between CMBs and amyloid deposition in 
the brain, reflected by low CSF Aβ42 or PET amyloid imaging65,78,90–92. The association with 
T-tau and P-tau is less clear. Patients with multiple CMBs (≥8) have shown higher P-tau and 
T-tau levels when compared to patients with zero CMBs91. This is contrary to our results, 
however differentiating based on CMB location might yield different data. Similarly, in study 
IV we showed an association between increased deep/infratentorial CMBs and low T-tau and 
P-tau, whereas Chiang et al showed high P-tau levels with lobar CMBs85. This makes sense 
as we show low T-tau and P-tau levels with deep/infratentorial CMBs in AD as well as in AD 
and VaD with hypertension. In patients with hypertension there was no association between 
Aβ42 and CMBs, further supporting the fact that hypertensive arteriopathy is different from 
amyloid pathology and the associated neurodegeneration. 
 20 
WMH was also related to lower CSF Aβ42 levels in independent regression analysis. WMH 
has shown to predict AD and cognitive impairment independently93–95, and the association 
seen is rational. High CSF/serum albumin ratio with WMH may indicate that WMH is 
associated with a disruption of the BBB30. High Aβ42 levels were associated with lacunes, 
suggesting that lacunes mostly are associated with hypertensive arteriopathy, and are not as 
often related to CAA30.  
Strengths of our study include a large cohort, thorough diagnosis and imaging ratings. 
Limitations include the use of different MRI scanners and field strengths, which however 
were controlled for in our regression analysis. Further, as diagnoses was set in 
multidisciplinary rounds with access to all data this may have led to circular reasoning and 
classification of patients in diagnostic groups based on for instance imaging findings.  
Study IV: We show that lobar CMBs are associated with low Aβ42 levels and that 
deep/infratentorial are associated with high Aβ42 levels. This corroborates the theory of 
region based SVD, with lobar CMBs representing CAA and deep/infratentorial CMBs 
hypertensive arteriopathy.  
There are to date few studies on the topography of CMBs and associations with CSF 
biomarkers. Lobar CMBs are associated with higher amyloid in the brain, reflected either by 
CSF or PET imaging85,96,97. P-tau has shown to be higher with CMBs in lobar brain regions85, 
and it is rational that CAA and the accompanying neurodegeneration would be associated 
with elevated tau levels. In more detailed topographies, especially occipital CMBs showed an 
association with lower Aβ42 levels and a high CSF/serum albumin ratio; this is reasonable 
since CAA has a predilection for the occipital lobe27,65,98. Meanwhile deep/infratentorial 
CMBs show associations with high Aβ42 and low T-tau and P-tau levels, and this supports 
the idea of differing underlying pathology of hypertensive arteriopathy. Aβ42 levels 
predicting lobar CMBs as well as CAA-related and -unrelated CMBs, but not deep, 
additionally support the association of amyloid and lobar CMBs. Suggestively, lobar CMBs 
are of more importance to study, considering the relation to CAA/neurodegeneration in 
cognitive impairment, although CMBs due to hypertensive arteriopathy may have an 
overlapping additional effect.  
Strengths of our study include a large cohort, thorough diagnosis and imaging analysis. 
Negatives are the use of different MRI field strengths as well as CMB sequences, which 
however were corrected for in the different analyses. 
General: Cerebral microbleeds are a common marker in cognitive impairment. The 
associations shown in cognitive impairment suggest that mainly lobar CMBs, i.e. CAA, is of 
importance in cognitive impairment, although hypertensive arteriopathy may have a 
synergistic contributing effect. It is however important to consider all markers of SVD, as 
detailed in figure 8, and the independent role of CMBs in this spectrum. The pattern of 
associations and their timely manifestation in cognitive impairment is another important 
aspect, necessitating further investigation. If SVD is a significant part of cognitive 
impairment, it should, similarly to disease pathophysiology, be evident in the preclinical 
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stages of disease. It is also important to realize the overlap between cognitive impairment and 
small vessel disease, and the fact that it may be hard to tease apart the respective effects.  
CAA being most important, and especially involved in AD pathology, is reflected by our data 
with association to CSF biomarkers, and the lack of association when including hypertensive 
arteriopathy. However hypertensive arteriopathy may still cause neurodegeneration and brain 
related damage on its own.  
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6 CONCLUSIONS  
 
Study I: CMBs are common in a memory clinic and show varying risk factor associations 
and topography depending on underlying dementia diagnosis.   
 
Study II: SWI has higher sensitivity for CMBs compared with T2*, and on the basis of this 
we recommend SWI as the sequence for CMB detection. Inter-rater agreement is excellent 
across sequences. Clinical associations with CMBs are comparable across SWI and T2*, 
suggesting that studies on CMBs using differing sequences can be compared.  
 
Study III: CMBs are primarily associated with lower CSF Aβ42 levels, and there is an 
accumulating effect with increased number of CMBs. CSF/serum albumin ratios are high 
with CMBs, possibly reflecting a disrupted blood brain barrier. There is no effect on T-tau 
and P-tau.  
 
Study IV: Lobar CMBs are associated with low CSF Aβ42 levels, and deep/infratentorial 
with lower T-tau and P-tau levels. Our study supports the theory of lobar CMBs being 
associated with CAA and deep/infratentorial with hypertensive arteriopathy.  
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7 FUTURE ASPECTS 
SVD, and the accompanying imaging markers, have long been overlooked and considered a 
normal finding in the brain. The implications, associations and longitudinal outcomes of SVD 
are however in need of more investigation, not only in cognitive impairment, but also in 
patients with stroke and cardiovascular disease.  
This thesis has been the start of the KIDS, a series of studies on dementia and imaging 
markers, to help aid and better understand dementia and its progression from cognitive 
impairment. We have to date multiple studies on the same topic that are accepted, in 
manuscript, or currently being pursued. Our future studies aim to determine the effects of all 
SVD imaging markers on cognitive impairment, as well as in patients with stroke. We further 
aim to longitudinally study SVD and the outcomes in both these groups. SVD is still a field 
where there is uncertainty regarding the effects and implications, as well as current treatment, 
and we aim to fill the knowledge gap by our research. 
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